Arcutis Biotherapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.01.25	Arcutis Biotherapeutics Projects Surge In Q4 Revenue Growth (RTTNews)
21.10.24	Arcutis: Health Canada Approves ZORYVE For Treatment Of Seborrheic Dermatitis (RTTNews)
25.09.24	Arcutis : ZORYVE Cream 0.15% Improves Atopic Dermatitis Across Skin Types In Phase 3 Trials (RTTNews)
28.08.24	Arcutis Reports Positive Results For Integument Study Of Roflumilast Cream 0.05% In AD In Children (RTTNews)
29.07.24	Arcutis Biotherapeutics Commercially Launches Zoryve Cream 0.15% For Atopic Dermatitis (RTTNews)
09.07.24	Arcutis Expects FDA's Action Letter For Roflumilast SNDA Indicated For Atopic Dermatitis (RTTNews)
03.07.24	Arcutis Nears FDA Decision On Roflumilast Cream For Atopic Dermatitis (RTTNews)
28.06.24	Biotech Stocks Facing FDA Decision In July 2024 (RTTNews)
10.04.24	Arcutis Biotherapeutics Appoints David Topper To Succeed John Smither As CFO (RTTNews)
30.11.23	Biotech Stocks Facing FDA Decision In December 2023 (RTTNews)
29.11.23	Arcutis Biotherapeutics: FDA To Review SNDA For Roflumilast Cream 0.15% (RTTNews)
06.10.23	Arcutis Receives FDA Approval For Its SNDA ZORYVE (RTTNews)
19.09.23	Arcutis' INTEGUMENT-PED Phase 3 Study Of Roflumilast Cream 0.05% Meets Primary Goal (RTTNews)
07.09.23	Arcutis Reports Results From INTEGUMENT-OLE Long-term Extension Trial Of Roflumilast Cream 0.15% (RTTNews)
01.12.22	MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis (PR Newswire)
08.09.22	LifeArc's Ducentis BioTherapeutics Agrees To Be Acquired By Arcutis For Up To $400 Mln (RTTNews)
08.09.22	LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million (PR Newswire)
30.08.22	NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING (PR Newswire)
29.07.22	FDA Approves Arcutis' ZORYVE Cream For Treatment Of Plaque Psoriasis In Patients 12 Years And Older (RTTNews)
11.07.22	Arcutis: Health Canada Accepts NDS For Roflumilast Cream To Treat Plaque Psoriasis (RTTNews)
11.07.22	Arcutis Says Health Canada Accepts For Review Roflumilast Cream NDS For Plaque Psoriasis (RTTNews)
28.06.22	Biotech Stocks Facing FDA Decision In July 2022 (RTTNews)
01.07.21	Arcutis To Terminate Phase 2a Clinical Trial Evaluating ARQ-252 Cream To Treat Vitiligo (RTTNews)
02.02.21	ADMS Gets FDA Nod, ARQT Soars On Psoriasis Trial Data, DVAX Catches Eye, PRTA On Watch (RTTNews)
24.11.20	AZN's COVID Shot 70% Effective On Average, ARQT Aces Scalp Psoriasis Study, BLRX' BLAST Fizzles (RTTNews)
02.10.20	Stock Alert: Arcutis Biotherapeutics Falls 15% (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	4’034.00	5.66 %	K V
Nestle	77.56	3.86 %	K V
Novartis	92.22	2.17 %	K V
Zurich Insur Gr	547.60	1.94 %	K V
Roche Hldg G	279.30	1.60 %	K V
Logitech Intl	82.36	-0.19 %	K V
Holcim	90.52	-0.77 %	K V
Lonza Grp	585.60	-0.91 %	K V
Part Grp Hldg	1’362.00	-1.98 %	K V
ABB	50.84	-5.85 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Arcutis Biotherapeutics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten